IBD--MUCOSA-SPECIFIC REGULATION OF IFN-GAMMA PRODUCTION

IBD--粘膜特异性的 IFN-γ 产生调节

基本信息

  • 批准号:
    6288345
  • 负责人:
  • 金额:
    $ 30.6万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2001
  • 资助国家:
    美国
  • 起止时间:
    2001-03-01 至 2005-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION: (Adapted from the Applicant's Abstract): T-cell production of IFN-gamma plays an essential role in disease initiation and severity of disease in animal models and Crohn's disease. Mucosal T-cells are different from peripheral T-cells in several ways. Mucosal T-cells are muted responders to activation via the T-cell receptor and are CD2 pathway dominant. During the previous award period the investigators used their ability to transfect primary T-cells to show unique mucosa-specific mechanisms by which T-cells produced Th1 cytokines. They demonstrated a role for AP1 in CD2 transactivation of the IL-2 gene. They showed that enhanced IL-2 production by CD2/CD28 co-activated peripheral T-cells occurs through mRNA stabilization and trans-activation in peripheral T-cells, however, in mucosal T-cells this effect can be solely the result of mRNA stabilization. This difference is due to the lack of activation of the AP1 and CD28 response elements in the IL-2 promotor in mucosal cells. They demonstrated several mucosal-specific mechanisms of IFN-gamma regulation and identified a unique role for TNF-alpha in mucosal T-cell IFN-gamma regulation. They defined the lamina propria mononuclear cell factor which can prime T-cells to respond to TNF-alpha. Furthermore, they demonstrated different cis elements in the IFN-gamma promotor that are used for transactivation of the IFN-gamma gene and mucosal T-cells as compared to peripheral T-cells. Finally, they demonstrated for the first time the enhancer function of the first intronic region of the IFN-gamma gene that involves the JAK/STAT pathway in mucosal T-cells but not in peripheral T-cells. Because of the vital importance of IFN-gamma in disease related mucosal inflammation yet its critical role for host defense, the knowledge of mucosa-specific targets, which would selectively attenuate mucosal IFN-gamma production without eliminating, would be a significant accomplishment. The overall objective of this continuation proposal is to more precisely define the mucosal specific regulatory pathways that are important for IFN-gamma regulation in T-cells and to use this knowledge to design approaches to modify IFN-gamma production in a mucosa-specific manner. This will be accomplished by the following specific aims: To identify through fine promotor analysis positive and negative cis-regulatory regions within the IFN-gamma promotor in which transcriptional regulation in lamina propria mononuclear cells differ from that in peripheral blood lymphocytes focusing on the previously identified regions of -204 to -108 (enhancer) and -528 to -204 base pair (repressor). To determine the mucosa-specific mechanisms of regulating the first intronic region of the IFN-gamma gene. From the results of Aim 1 and Aim 2 design molecular approaches including transfection of antisense oligonucleotides and or dominant negative transacting factors to attenuate in vitro IFN-gamma promotor expression in a mucosal-specific manner.
描述:(根据申请人的摘要改编): IFN-gamma在疾病开始和疾病严重程度中起着至关重要的作用 在动物模型和克罗恩病。粘膜T细胞不同于 外围T细胞有几种方式。粘膜T细胞是反应者 通过T细胞受体的激活,是CD2途径的主导性。在 以前的奖项期调查人员使用其转染的能力 T细胞显示出独特的粘膜特异性机制,T细胞产生Th1 细胞因子。他们证明了AP1在IL-2的CD2反式激活中的作用 基因。他们表明,CD2/CD28共激活IL-2的产生增强 周围T细胞通过mRNA稳定和反式激活发生 但是,外围T细胞,在粘膜T细胞中,这种效应只能是 mRNA稳定的结果。这种差异是由于缺乏激活 粘膜细胞中IL-2启动子中的AP1和CD28响应元件的。 他们证明了IFN-gamma调节的几种粘膜特异性机制 并确定了TNF-Alpha在粘膜T细胞IFN-Gamma中的独特作用 规定。他们定义了固定层单核细胞因子 Prime T细胞应对TNF-Alpha。此外,他们证明了不同的 IFN-gamma启动子中用于反式激活的元素 与周围T细胞相比,IFN-GAMMA基因和粘膜T细胞。最后, 他们首次证明了第一个的增强功能 IFN-GAMMA基因的内含子区域,涉及jak/stat途径 粘膜T细胞,但不在外周T细胞中。因为至关重要 IFN-Gamma在疾病相关的粘膜炎症中的关键作用 宿主防御,粘膜特定目标的知识,这将有选择地 衰减粘膜IFN-gamma生产而不消除,将是 重大成就。该延续建议的总体目标 是更精确地定义粘膜特定的调节途径 对于T细胞中的IFN-Gamma调节很重要,并将这些知识用于 设计方法以粘膜特异性方式修饰IFN-gamma生产。 这将通过以下具体目的来完成:通过 精细的启动子分析阳性和负顺式调节区域 IFN-gamma启动子在层次中转录调节 单核细胞与关注的外周血淋巴细胞不同 以前确定的区域为-204至-108(增强器)和-528至-204 基对(阻遏物)。确定粘膜特异性机制 调节IFN-GAMMA基因的第一个内含子区域。从结果 AIM 1和AIM 2设计分子方法,包括反义转染 在 体外IFN-gamma启动子以粘膜特异性方式表达。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Stephan R. Targan其他文献

Serial 6-mercaptopurine (6-MP) metabolite measurements in combination with dose escalation unmasks an important biochemical explanation for "6-MP resistance"
  • DOI:
    10.1016/s0016-5085(00)85698-x
  • 发表时间:
    2000-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Marla C. Dubinsky;Philip V. Hassard;Lori Y. Kam;Maria T. Abreu;Ernest G. Seidman;Stephan R. Targan;Eric A. Vasiliauskas
  • 通讯作者:
    Eric A. Vasiliauskas
Thioguanine (6-TG): A therapeutic alternative in a subgroup of IBD patients failing 6-mercaptopurine (6-MP)
  • DOI:
    10.1016/s0016-5085(00)85701-7
  • 发表时间:
    2000-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Marla C. Dubinsky;Philip V. Hassard;Maria T. Abreu;Lori Y. Kam;Ernest G. Seidman;Stephan R. Targan;Eric A. Vasiliauskas
  • 通讯作者:
    Eric A. Vasiliauskas
Tu1740 – Sustained Remission in Patients with Moderate to Severe Ulcerative Colitis: Results from the Phase 3 Unifi Maintenance Study
  • DOI:
    10.1016/s0016-5085(19)39726-4
  • 发表时间:
    2019-05-01
  • 期刊:
  • 影响因子:
  • 作者:
    Gert A. Van Assche;Stephan R. Targan;Thomas Baker;Christopher D. O'Brien;Hongyan Zhang;Jewel Johanns;Philippe Szapary;Colleen W. Marano;Rupert W. Leong;David Rowbotham;Tadakazu Hisamatsu;Silvio Danese;Bruce E. Sands;Laurent Peyrin-Biroulet
  • 通讯作者:
    Laurent Peyrin-Biroulet
Tu1764 - Tl1A Deficiency (But not Dr3-Deficiency) Protects from the Development of Colitis in the Chronic T Cell Transfer Mouse Model by Decreasing Th1 Cell Accumulation in the Intestinal Mucosa
  • DOI:
    10.1016/s0016-5085(18)33390-0
  • 发表时间:
    2018-05-01
  • 期刊:
  • 影响因子:
  • 作者:
    Yosuke Shimodaira;Yoshitake Kanazawa;Jay P. Abraham;Kotaro Kumagai;Noam Jacob;Yuefang Ye;Justin Luu;Kathrin S. Michelsen;Stephan R. Targan;David Shih
  • 通讯作者:
    David Shih
Tu1797 - Multi-Center Cohort Analysis Identified a Genetic Association in Complement Factor B with Perianal Crohn's Disease
  • DOI:
    10.1016/s0016-5085(18)33423-1
  • 发表时间:
    2018-05-01
  • 期刊:
  • 影响因子:
  • 作者:
    Marcy Akhlaghpour;Talin Haritunians;Emebet Mengesha;Dalin Li;Zhenqiu Liu;Randall McNally;Carol Landers;Karen Zaghiyan;Phillip Fleshner;Gil Melmed;Stephan R. Targan;Mark S. Silverberg;Kathrin S. Michelsen;Dermot McGovern
  • 通讯作者:
    Dermot McGovern

Stephan R. Targan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Stephan R. Targan', 18)}}的其他基金

Mechanisms of TL1A-driven Paneth Cell dysfunction in IBD
IBD 中 TL1A 驱动的潘氏细胞功能障碍的机制
  • 批准号:
    10077845
  • 财政年份:
    2020
  • 资助金额:
    $ 30.6万
  • 项目类别:
Mechanisms of TL1A-driven Paneth Cell dysfunction in IBD
IBD 中 TL1A 驱动的潘氏细胞功能障碍的机制
  • 批准号:
    10539302
  • 财政年份:
    2020
  • 资助金额:
    $ 30.6万
  • 项目类别:
Mechanisms of TL1A-driven Paneth Cell dysfunction in IBD
IBD 中 TL1A 驱动的潘氏细胞功能障碍的机制
  • 批准号:
    10311509
  • 财政年份:
    2020
  • 资助金额:
    $ 30.6万
  • 项目类别:
Molecular characterization of the role of RNASET2 in Severe Crohn's Disease
RNASET2 在严重克罗恩病中作用的分子表征
  • 批准号:
    10021036
  • 财政年份:
    2019
  • 资助金额:
    $ 30.6万
  • 项目类别:
Molecular characterization of the role of RNASET2 in Severe Crohn's Disease
RNASET2 在严重克罗恩病中作用的分子表征
  • 批准号:
    10226172
  • 财政年份:
    2019
  • 资助金额:
    $ 30.6万
  • 项目类别:
Role of TRIF-Dependent TLR Signaling in Intestinal Mucosa
TRIF 依赖性 TLR 信号转导在肠粘膜中的作用
  • 批准号:
    10225616
  • 财政年份:
    2012
  • 资助金额:
    $ 30.6万
  • 项目类别:
IBD: Mucosa Specific Regulation of IFN-gamma Production
IBD:粘膜对 IFN-γ 产生的特异性调节
  • 批准号:
    7921223
  • 财政年份:
    2009
  • 资助金额:
    $ 30.6万
  • 项目类别:
INFLAMMATORY BOWEL DISEASE CENTER: CLINICAL DATA REPOSITORY - TISSUE PROCUREMENT
炎症性肠病中心:临床数据存储库 - 组织采购
  • 批准号:
    8174459
  • 财政年份:
    2009
  • 资助金额:
    $ 30.6万
  • 项目类别:
INFLAMMATORY BOWEL DISEASE CENTER: CLINICAL DATA REPOSITORY - TISSUE PROCUREMENT
炎症性肠病中心:临床数据存储库 - 组织采购
  • 批准号:
    7952200
  • 财政年份:
    2008
  • 资助金额:
    $ 30.6万
  • 项目类别:
CORE--TISSUE PROCUREMENT & DATA ANALYSIS & SERUM ANALYSIS
核心——纸巾采购
  • 批准号:
    7487329
  • 财政年份:
    2007
  • 资助金额:
    $ 30.6万
  • 项目类别:

相似海外基金

IBD--MUCOSA-SPECIFIC REGULATION OF IFN-GAMMA PRODUCTION
IBD--IFN-γ产生的粘膜特异性调节
  • 批准号:
    6687840
  • 财政年份:
    2001
  • 资助金额:
    $ 30.6万
  • 项目类别:
IBD--MUCOSA-SPECIFIC REGULATION OF IFN-GAMMA PRODUCTION
IBD--粘膜特异性的 IFN-γ 产生调节
  • 批准号:
    6626937
  • 财政年份:
    2001
  • 资助金额:
    $ 30.6万
  • 项目类别:
IBD--MUCOSA-SPECIFIC REGULATION OF IFN-GAMMA PRODUCTION
IBD--IFN-γ产生的粘膜特异性调节
  • 批准号:
    6829097
  • 财政年份:
    2001
  • 资助金额:
    $ 30.6万
  • 项目类别:
IBD--MUCOSA-SPECIFIC REGULATION OF IFN-GAMMA PRODUCTION
IBD--IFN-γ产生的粘膜特异性调节
  • 批准号:
    6489654
  • 财政年份:
    2001
  • 资助金额:
    $ 30.6万
  • 项目类别:
T CELL TARGETING FOR GVHD
T 细胞靶向 GVHD
  • 批准号:
    6043892
  • 财政年份:
    1995
  • 资助金额:
    $ 30.6万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了